COX-2 rs689466 polymorphism correlates with increased lung cancer risk

Background: The aim of this study was to assess, using comprehensive meta-analysis, if there was a significant association between polymorphisms in cyclooxygenase-2 (COX-2) gene and lung cancer risk. Methods: PubMed, MEDLINE, EMBASE, Web of Science, CBM, CNKI, WanFang, and CQVIP were searched for all eligible studies through July 2018. A total of 612 citations were retrieved. Odds ratios (OR) and corresponding 95% confidence intervals (CIs) were utilized to evaluate the strength of association between COX-2 gene polymorphisms and lung cancer risk. Meta-analysis, sensitivity analysis, Begg's funnel plot, Egger's linear regression, and subgroup analyses were carried out to clarify and validate pooled results. Results: A total of 8 studies met the inclusion criteria and were included in the meta analysis. This current systematic review indicated that COX-2 rs689466 polymorphism correlates with increased lung cancer risk in the allele model (A vs. G), dominant model (AA vs. GG/AG), and homozygous model (AA vs. GG). According to subgroup-analysis, the AA genotype of COX-2 gene rs689466 site increased lung cancer risk in Asian populations, population-based, and hospital-based. Conclusion: COX-2 rs689466 site may moderately increase the risk of lung cancer, especially in Asian populations, PB, and HB studies. In addition, AA homozygotes may contribute to early diagnosis and prevention, providing timely treatments. Results suggest that COX-2 rs689466 polymorphism may be a potential pathogenic factor in lung cancer.